45.13
Schlusskurs vom Vortag:
$44.98
Offen:
$45.105
24-Stunden-Volumen:
6.47M
Relative Volume:
0.33
Marktkapitalisierung:
$65.40B
Einnahmen:
$20.62B
Nettoeinkommen (Verlust:
$3.56B
KGV:
18.92
EPS:
2.3847
Netto-Cashflow:
$3.48B
1W Leistung:
-6.76%
1M Leistung:
-8.54%
6M Leistung:
-37.27%
1J Leistung:
-58.28%
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, MDT, SYK, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp
|
45.13 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
ABT
Abbott Laboratories
|
105.82 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
92.35 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
272.56 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
EW
Edwards Lifesciences Corp
|
86.18 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
BSX Maintains Buy Rating by BTIG -- Price Target Lowered to $56 - GuruFocus
Update on recent cybersecurity incident - Boston Scientific
Boston Scientific Corp (BSX) Stock Down 5.9% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack - theinsurer.com
Boston Scientific Flags Guidance Miss Amid 'Material Impact' From Cybersecurity Incident; Shares Fall - Yahoo! Finance Canada
Boston Scientific misses 2026 guidance after cyberattack - Yahoo Finance
Boston Scientific Says Cyberattack Will Impact 2026 Results — Says It Is ‘Unlikely’ To Meet Net Sales Growth, EPS Guidance Ranges - Yahoo Finance
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack - Benzinga
Boston Scientific stock falls after 2026 guidance cut - AD HOC NEWS
Damages from med-tech cyberattacks adding up - BioWorld News
Boston Scientific left nursing its bottom line after cyberattack - The Register
Boston Scientific Unlikely to Meet Forecasts After Cyber Attack - Bloomberg.com
Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers - Yahoo Finance
Boston Scientific Warns On Earnings After Cyberattack - baystreet.ca
Boston Scientific Says Cyberattack Will Hit Q3 and FY2026 Results and Miss Guidance - Minichart
Boston Scientific Shares Slide After Cyberattack Forces 2026 Guidance Cut - AskTraders
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead? - Yahoo Finance
Boston Scientific says cyberattack likely to hurt 2026 sales, profit By Reuters - Investing.com
Boston Scientific unlikely to meet guidance due to cyberattack - Yahoo Finance
Boston Scientific Unlikely to Meet Net Sales Guidance as Cybersecurity Incident Disrupts Operations - marketscreener.com
Boston Scientific CorpIdentifies Cybersecurity Incident Causing Global Operational DisruptionSEC Filing - TradingView
Boston Scientific Won't Meet Guidance Due to Cyberattack - marketscreener.com
Boston Scientific unlikely to meet Q3FY26 and full-year guidance - scanx.trade
Boston Scientific Won’t Meet Guidance Due to Cyberattack - Yahoo Finance
Why is Boston Scientific stock sliding today? - Investing.com
Why is Boston Scientific stock sliding today? By Investing.com - Investing.com UK
Boston Scientific says cyberattack likely to hurt 2026 sales, profit - marketscreener.com
Boston Scientific says cyberattack likely to hurt 2026 sales, profit targets - marketscreener.com
Cyberattack forces Boston Scientific (NYSE: BSX) to rethink its 2026 outlook - Stock Titan
TD Cowen reiterates Boston Scientific stock Buy rating after cyber recovery - Investing.com Canada
Boston Scientific on road to recovery following cyberattack - Yahoo Finance
Boston Scientific stock holds steady as investors weigh latest medical-device growth story - AD HOC NEWS
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Zacks Investment Research
Boston Scientific stock gains support from institutional buying and solid Q2 2026 results - AD HOC NEWS
Recall Recap: Boston Scientific Pacemakers, Baby Formula - Law360
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
TD Cowen reiterates Boston Scientific stock rating on shipping restoration - Investing.com
Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk - Benzinga
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
Boston Scientific (NYSE:BSX) Trades Below Its Cash-Flow Value - Kalkine Media
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue? - Yahoo Finance
Boston Scientific Corp Stock Price Live, Charts & News - economictimes.indiatimes.com
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific (BSX) Could Be 23% Undervalued After Recalls And Cyber Incident - Yahoo Finance
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Boston Scientific (BSX) Issues Multiple Worldwide Product Recalls - Yahoo Finance
Vanguard PRIMECAP Fund's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific (NYSE:BSX) Closes In on Its Landmark Penumbra Deal - kalkinemedia.com
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks? - Barchart.com
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):